EMEA approves Prozac for Children
The European Medicines Agency (EMEA) has approved the use of Prozac (fluoxetine) and other serotonin selective re-uptake inhibitor (SSRI) medicines to treat children
The European Medicines Agency (EMEA) has approved the use of Prozac (fluoxetine) and other serotonin selective re-uptake inhibitor (SSRI) medicines to treat children of 8 years and over who do not respond to psychological therapy. The Agency%s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of using Prozac in this therapy area outweigh its potential risks, but added that the marketing authorization holder (MAH), Eli Lilly, should carry out additional studies to ensure that the safety profile of Prozac remains acceptable.
Prozac and other SSRIs are authorized in most EU Member States for the treatment of major depressive episodes, obsessive-compulsive disorder and bulimia nervosa in adults. Following a request from the UK, the MAH for Prozac submitted an application to extend the indications to include the treatment of major depressive episodes in children and adolescents. CHMP was asked by France to begin an arbitration review on the basis of unresolved safety and efficacy concerns.
Based on the data reviewed the CHMP found that the studies in children and adolescents were positive, but added that if no clinical benefit was observed within 9 weeks the treatment should be re-assessed. The CHMP emphasized that doctors and parents should carefully monitor children and adolescents for suicidal behaviour, particularly at the beginning of treatment.
www.emea.eu.int
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Amgen’s Imdelltra Demonstrates Significant Overall Survival Improvement in Small Cell Lung Cancer
April 16th 2025In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically significant and clinically meaningful improvement in overall survival compared to standard-of-care chemotherapy.
